Deepbridge announces 24 life sciences companies funded in past 12 months
Tax-efficient investment manager Deepbridge Capital has today announced it has successfully raised funds for twenty four life sciences companies within the last twelve months, via the Deepbridge Life Sciences SEIS proposition.
The Deepbridge Life Sciences SEIS provides financial advisers and private investors the opportunity to invest in a portfolio of early stage life sciences investments, whilst benefitting from the significant potential tax reliefs available via the Government’s Seed Enterprise Investment Scheme.
As part of this, Deepbridge has seeded Acorn Partners in collaboration with Alder Hey Children’s Hospital and digital experts WeAreNova. Acorn is seen as an efficient new way of originating, developing and delivering innovation within the broader healthcare space.
Dr Savvas Neophytou, Partner and Head of Life Sciences, commented:
“We are delighted to have completed investment in 24 new life sciences companies over the past year. The companies we carefully chose to invest in range from seed-stage companies to multi-million commercialization-stage funding. Within these twenty four companies, we have a mixture of diagnostic technology, drug discovery, treatment innovation and e-health projects. Working in partnership with Europe’s largest children’s hospital is particularly exciting.
“We have been delighted with the response we have had from financial advisers and investors to our Deepbridge Life Sciences SEIS. With Government having pledged to maintain funding levels for life sciences post-Brexit, there has never been greater need for initiatives like the (Seed) Enterprise Investment Scheme to provide funding for healthcare and life sciences innovation. But, investors considering investing should seek to invest alongside those experienced in this sector as it is a unique market that requires particular experience.”